+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vector Manufacturing - Global Market Trajectory & Analytics

  • ID: 4806192
  • Report
  • February 2022
  • Region: Global
  • 402 Pages
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Batavia Biosciences B.V.
  • Cobra Biologics Ltd.
  • Genelux Corporation
  • Lonza Group AG
  • Merck KGaA
  • Oxford BioMedica plc

Global Viral Vector Manufacturing Market to Reach $1.2 Billion by 2026


Viral vectors are tools that find common usage in molecular biology related research, for the main purpose of delivering genetic materials to cells. The process of delivery is performed in vivo or inside the living organism and also in vitro or within cell culture. Viruses were able to evolve distinct molecular mechanisms which allow effective transmission of their genomes in the cells that they infect. The process of genetic material or genes delivery using a vector is called transduction. The cells that are infected are referred to as the transduced. Viral vectors were used by molecular biologists as early as in the 70s. SV40, a modified virus with DNA from bacteriophage ?, was used for infecting cells in monkey kidney. Viral vectors are currently being used for vaccines development and gene therapy in addition to their use in molecular biology. Though viral vectors are generally customized to suit specific applications, they have certain common properties in terms of safety, stability, toxicity, cell type specificity and identification. Usually, viral vectors are derived from viruses that are pathogenic. Modification is done to minimize risks while handling. Modification involves elimination of a viral genome part that is important for the replication of the virus. A modified virus requires helpers to produce new versions and therefore only effective for so long as to infect the cells. Another important property of viral vectors is that they are of low toxicity, having limited impact on cell physiology. Also, certain viruses are unstable genetically. They rearrange genomes rapidly which can be damaging to reproducibility and predictability of work done using viral vectors.

Amid the COVID-19 crisis, the global market for Viral Vector Manufacturing estimated at US$450.5 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2026, growing at a CAGR of 18.5% over the analysis period. Retroviral Vectors, one of the segments analyzed in the report, is projected to record a 18.5% CAGR and reach US$547.1 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adenoviral Vectors segment is readjusted to a revised 18.8% CAGR for the next 7-year period.



The U.S. Market is Estimated at $327.6 Million in 2021, While China is Forecast to Reach $49 Million by 2026


The Viral Vector Manufacturing market in the U.S. is estimated at US$327.6 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$49 Million by the year 2026 trailing a CAGR of 21.9% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.8% and 16% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.

The increasing prevalence of various genetic disorders and target diseases such as infectious diseases, increased funding availability for development of gene therapy, research efforts in the field of viral vector based cell and gene therapies, and increasing efficacy of viral vectors in delivering gene therapy are fueling growth in the global viral vectors manufacturing market. The growing investments into biopharmaceutical production, rising healthcare spending, technology advancements and healthcare needs of aging population are fueling growth in the viral vectors market. Rise in number of clinical studies, and potential applications in novel drug delivery approaches are also fueling growth in the market. Several viral vector-based drugs have already been approved including Gendicine™, which is the foremost gene therapy drug based on oncolytic adenovirus vector; StrimvelisR, a lentivirus vector for severe combined immunodeficiency (SCID); GlyberaRR, a recombinant AAV for addressing lipoprotein lipase deficiency.

Adeno-Associated Viral Vectors Segment to Reach $287.8 Million by 2026


AAVs or adeno-associated viruses are those that infect primate species and humans commonly. Even though they do not cause major diseases and only result in a minor immune response, the viruses are able to infect non-dividing as well as dividing cells and incorporate virus genome into host cell. AAV also stays in the form of episomal mostly, performing stable and long expression - features which make the viruses attractive candidates for viral vectors` creation, to be used in gene therapy. In the global Adeno-associated Viral Vectors segment, USA, Canada, Japan, China and Europe will drive the 19.7% CAGR estimated for this segment. These regional markets accounted for a combined market size of US$89.5 Million in the year 2020. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.2 Million by the year 2026.

Select Competitors (Total 80 Featured) -

  • Batavia Biosciences B.V.
  • BioNTech IMFS GmbH
  • Cobra Biologics Ltd.
  • FinVector Oy
  • FUJIFILM Diosynth Biotechnologies
  • Genelux Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • MaxCyte, Inc.
  • Merck KGaA
  • Novasep Inc.
  • Oxford BioMedica plc
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Biolabs
  • Vigene Biosciences, Inc.
  • Virovek, Inc.
The global analysis and forecast periods covered within the report are 2020-2027 (Current & Future Analysis) and 2012-2019 (Historic Review). Research estimates are provided for 2020, while research projections cover the period 2021-2027.
Frequently Asked Questions about the Global Market for Viral Vector Manufacturing

What is the estimated value of the Global Market for Viral Vector Manufacturing?

The Global Market for Viral Vector Manufacturing was estimated to be valued at $450.5 Million in 2020.

What is the growth rate of the Global Market for Viral Vector Manufacturing?

The growth rate of the Global Market for Viral Vector Manufacturing is 17.7%, with an estimated value of $1200.0 Million by 2026.

What is the forecasted size of the Global Market for Viral Vector Manufacturing?

The Global Market for Viral Vector Manufacturing is estimated to be worth $1200.0 Million by 2026.

Who are the key companies in the Global Market for Viral Vector Manufacturing?

Key companies in the Global Market for Viral Vector Manufacturing include Batavia Biosciences B.V., BioNTech IMFS GmbH, Cobra Biologics Ltd., FinVector Oy, FUJIFILM Diosynth Biotechnologies, Genelux Corporation, Kaneka Eurogentec S.A., Lonza Group AG and Merck KGaA.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Batavia Biosciences B.V.
  • Cobra Biologics Ltd.
  • Genelux Corporation
  • Lonza Group AG
  • Merck KGaA
  • Oxford BioMedica plc

I. METHODOLOGY


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of COVID-19 Pandemic and Looming Global Recession
  • With Viral Vector-based Vaccines Used for COVID-19 in Development, Viral Vector Manufacturing Market Poised to Benefit
  • An Introduction to Viral Vector Manufacturing
  • Applications of Viral Vectors
  • Types of Viral Vectors
  • Global Viral Vector Manufacturing Market: Prospects & Outlook
  • Competition
  • COVID-19 Pandemic Puts Pressure on Already Constrained Viral Vector Manufacturing Capacity
  • A Glance at Select Investments in Expanding Viral Vector Manufacturing Capacity
  • Recent Market Activity
  • Viral Vector Manufacturing – Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Increasing Prevalence of Infectious Diseases, Genetic Disorders & Cancers Drives Market
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050)
  • Gene Therapy Emerges as a Major Therapeutic Approach for Inheritable and Acquired Diseases, Spurring Market Prospects
  • Gene Therapy Set to Witness Rapid Growth Post COVID-19
  • Viral Vectors Lead the Gene Therapy Market
  • Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
  • Lentiviral Vectors Witness Increased Interest for Gene Therapy
  • Funding Support for Gene Therapy Development Presents Market Opportunities
  • Complexity in Viral Vector Production for Gene therapies
  • Amidst Rising Cancer Incidence, Focus on Viral Vector-based Gene Therapies to Boost Market
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
  • Engineered and Natural Oncolytic Viral Vectors: A Key Development in Viral Vector-based Cancer Therapy
  • Growing Threat Posed by Infectious Diseases Drives Focus onto Vector Viral-based Therapies & Vaccines
  • Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
  • Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
  • Rising Significance of Viral Vectors in New Vaccine Development
  • Adenovirus-based Vaccines: Evolution Over the Years
  • Viral Vector Emerges as a Next-Gen Platform for COVID-19 Vaccines Development
  • Rush to Develop and Rollout COVID-19 Vaccines Boosts Prospects for Viral Vector Manufacturing
  • COVID-19 Vaccines Under Development
  • Vaccines in Pipeline by Technology
  • Vaccine Technologies in Pre-Clinical Studies
  • Replicating and Non-Replicating Viral Vector-Based Vaccines
  • Non-Replicating Viral vector Vaccine in Clinical Development: As on December 2nd, 2020
  • Replicating Viral vector Vaccine Candidate in Clinical Development: As on December 2nd, 2020
  • Adenoviral Vectors: Frontrunners of New Vaccine for COVID-19
  • Vaccines for COVID-19 Confronts Logistic Obstacles to Overcome
  • Market to Benefit from the Emergence of New Technologies to Manufacture Viral Vectors
  • New Trends for Optimizing Workflow Using Viral Vectors
  • Production Workflow & Viral Vectors
  • Closed-System-Adherent Culture of Cells: Recent Advances
  • Limitations in Viral Vector Manufacturing Impact Market
  • Innovations & Collaborations: Essential to Resolve Challenges Facing Large-Scale GMP Viral Vector Manufacturing

4. GLOBAL MARKET PERSPECTIVE


III. MARKET ANALYSIS

UNITED STATES

  • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)

CANADA

JAPAN

  • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)

CHINA

  • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)

EUROPE

  • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)

FRANCE

  • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)

GERMANY

  • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)

ITALY

UNITED KINGDOM

  • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)

REST OF EUROPE

ASIA-PACIFIC

  • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)

REST OF WORLD

IV. COMPETITION

  • Total Companies Profiled: 80
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Batavia Biosciences B.V.
  • BioNTech IMFS GmbH
  • Cobra Biologics Ltd.
  • FinVector Oy
  • FUJIFILM Diosynth Biotechnologies
  • Genelux Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • MaxCyte, Inc.
  • Merck KGaA
  • Novasep Inc.
  • Oxford BioMedica plc
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Biolabs
  • Vigene Biosciences, Inc.
  • Virovek, Inc.
Note: Product cover images may vary from those shown